Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Summary of patient safety in the PD-1 inhibitors group before PSM

From: Adjuvant PD-1 inhibitors improve recurrence and survival outcomes in high-risk hepatocellular carcinoma patients after curative hepatectomy

Adverse events

All grades, n (%)

Grade 1–2, n (%)

Grade 3–4, n (%)

All patients

32 (41.6)

22 (28.6)

10 (13.0)

Rash

6 (7.8)

4 (5.2)

2 (2.6)

Pruritus

10 (13.0)

7 (9.1)

3 (3.9)

Hypertension

2 (2.6)

1 (1.3)

1(1.3)

Fatigue

0 (0.0)

0 (0.0)

0 (0.0)

Diarrhea

6 (7.8)

5 (6.5)

1(1.3)

Decreased appetite

0 (0.0)

0 (0.0)

0 (0.0)

Proteinuria

1 (1.3)

1 (1.3)

0 (0.0)

Elevated ALT/AST

3 (3.9)

2 (2.6)

1 (1.3)

Elevated bilirubin

0 (0.0)

0 (0.0)

0 (0.0)

Hypothyroidism

3 (3.9)

1 (1.3)

2 (2.6)

Anemia

0 (0.0)

0 (0.0)

0 (0.0)

Thrombocytopenia

0 (0.0)

0 (0.0)

0 (0.0)

Decreased neutrophils

1 (1.3)

1 (1.3)

0 (0.0)

  1. PD-1 programmed cell death protein-1, PSM propensity score matching, ALT alanine aminotransferase, AST aspartate aminotransferase
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us